An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma

Trial Profile

An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Acalabrutinib (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 01 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 03 Mar 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
    • 03 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top